Anti-CD134 / OX40L Receptor Antibody [Ber-ACT35] (A279812)

Anti-CD134 / OX40L Receptor Antibody [Ber-ACT35]

Mouse monoclonal [Ber-ACT35] antibody to CD134 / OX40L Receptor.

This antibody recognises CD134 also known as OX40 and TNFRSF4, a 50 kDa glycoprotein. CD134 is a type I transmembrane protein and a member of the tumor necrosis factor superfamily. CD134 is primarily expressed by activated T cells, although the level of expression differs according to T-cell subpopulations. OX40L also known as CD252 and TNFSF4 is the ligand of CD134. Upon ligand binding, the receptor recruits TNF receptor associated factor (TRAF) proteins which triggers downstream signaling events including NF?B pathways. This activation can regulate the number of effector T cells that accumulate in primary and secondary responses and determine the frequency of T cells that are generated (Croft 2010). Mutations affecting CD134 signaling has been linked with Kaposi sarcoma as well as susceptibility to infections. This clone Ber-ACT35 has been used in flow cytometry experiments to measure D134 expression levels on tumor-infiltrating Treg cells in mouse and human samples.

Flow Cytometry, IHC-Fr, IP, WB, ELISA, IHC-P

Human, Primate

HTLV 1-transformed HUT-102 cells.

Mouse

Monoclonal

Ber-ACT35

IgG1

Protein A affinity chromatography of tissue culture supernatant.

>95% (by SDS-PAGE).

Liquid

Supplied in Phosphate Buffered Saline with <0.1% Sodium Azide.

Store undiluted at 4°C. Do not freeze!

Mouse anti Human CD134, clone Ber-ACT35 recognizes CD134 also known as OX40 and TNFRSF4, a 50 kDa glycoprotein. CD134 is a type I transmembrane protein and a member of the tumor necrosis factor superfamily. CD134 is primarily expressed by activated T cells, although the level of expression differs according to T-cell subpopulations (Buchan et al. 2018). OX40L also known as CD252 and TNFSF4 is the ligand of CD134. Upon ligand binding, the receptor recruits TNF receptor associated factor (TRAF) proteins which triggers downstream signaling events including NF?B pathways. This activation can regulate the number of effector T cells that accumulate in primary and secondary responses and determine the frequency of T cells that are generated (Croft 2010). Mutations affecting CD134 signaling has been linked with Kaposi sarcoma as well as susceptibility to infections. This clone Ber-ACT35 has been used in flow cytometry experiments to measure D134 expression levels on tumor-infiltrating Treg cells in mouse and human samples (Vargas et al. 2018).

ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, TNFRSF4, Tumor necrosis factor receptor superfamily member 4, TXGP1L